Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Net Cash Flow (2016 - 2025)

Sangamo Therapeutics has reported Net Cash Flow over the past 16 years, most recently at -$9.6 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$9.6 million for Q4 2025, down 293.8% from a year ago — trailing twelve months through Dec 2025 was -$26.6 million (down 2045.48% YoY), and the annual figure for FY2025 was -$26.6 million, down 2045.48%.
  • Net Cash Flow for Q4 2025 was -$9.6 million at Sangamo Therapeutics, down from -$9.4 million in the prior quarter.
  • Over the last five years, Net Cash Flow for SGMO hit a ceiling of $46.8 million in Q2 2021 and a floor of -$58.8 million in Q1 2022.
  • Median Net Cash Flow over the past 5 years was -$8.7 million (2021), compared with a mean of -$5.8 million.
  • Biggest five-year swings in Net Cash Flow: tumbled 633.08% in 2022 and later surged 220.71% in 2024.
  • Sangamo Therapeutics' Net Cash Flow stood at $2.0 million in 2021, then soared by 150.81% to $5.1 million in 2022, then crashed by 348.34% to -$12.7 million in 2023, then surged by 139.2% to $5.0 million in 2024, then tumbled by 293.8% to -$9.6 million in 2025.
  • The last three reported values for Net Cash Flow were -$9.6 million (Q4 2025), -$9.4 million (Q3 2025), and $10.4 million (Q2 2025) per Business Quant data.